Paliperidone palmitate-induced sialorrhoea

Temel Bulgular & Veri:Paliperidona bağlı siyalore bildiren az sayıda kaynağa rastlanmasına karşın paliperidon palmitata bağlı siyalore bildiren kaynağa rastlanmamıştır.

💡

Sonuç & Katkı:Bu yazımızda kliniğimize başvuran ve paliperidon palmitat başladığımız bir hastada gelişen siyalore yan etkisi sunulmuştur

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Özet

Atipik antipsikotiklere ilişkin ekstrapiramidal, metabolik ve kardiyak yan etkiler bildirilmiştir. Paliperidona bağlı siyalore bildiren az sayıda kaynağa rastlanmasına karşın paliperidon palmitata bağlı siyalore bildiren kaynağa rastlanmamıştır. Bu yazımızda kliniğimize başvuran ve paliperidon palmitat başladığımız bir hastada gelişen siyalore yan etkisi sunulmuştur

Abstract

Extrapyramidal, metabolic, and cardiac side effects were reported for atypical antipsychotics; although a few resources show paliperidone-induced sialorrhea, there are no resources that show paliperidone palmitate-induced sialorrhea. In this paper, we present the paliperidone palmitate-induced sialorrhea side effects of a patient who applied on our clinic

🔖

Bu Makaleye Atıf Yap

ÖZENLİ, Y., TUĞAL, Ö., CENGİSİZ, C. (2022). Paliperidone palmitate-induced sialorrhoea. Çukurova Üniversitesi Tıp Fakültesi Dergisi, Cilt: 41 - Sayı: ek 1, 8–13. https://ajindex.com/articles/478145

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. Lancet. 2009;373:31-41
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23
FDA Approves New Drug for Schizophrenia [Internet] [cited 2015 Nov 26] Available from: http://www.fda.gov/NewsEvents/Newsroom/Pres sAnnouncements/2006/ucm108812.htm 4. Taylor D, Paon C, Kapur S. The Maudsley Prescribing Guidelines. 10th Edition. London: Informa Healthcare, 2009;15
Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd Edition. New York, NY, Cambridge University Press, 2008
Hough D, Lindenmayer J-P, Gopal S, Melkote R, Lim P, Herben V et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1022–31
Vermeule A, Wouters A. Patent of dosing regimen association with long acting injectable paliperidone esters. 2009;US20090163519A
Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry. 2004;65:120–11
Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M et al. A controlled, evidence-based trial of paliperidone palmitate, a longacting injectable antipsychotic, in schizophrenia. Neuropsychopharmacol 2010;35:2072–82
Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-torelapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116:107-17
Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin. 2010;26:377-330
Megens AA, Awouters FHL. In vivo pharmacological profile of 9-hydroxy-risperidone the major metabolite of the novel antipsychotic risperidone. Drug Dev Res. 1994;33:399-412
Invega® Product Information. Janssen Pharmaceuticals. [Internet] [cited 2015 Dec 16] Available from:
Bavikatte G, Sit PL, Hassoon A. Management of drooling of saliva.